Literature DB >> 6447230

Pathopysiological aspects of immune complex diseases. Part II. Phagocytosis, exocytosis, and pathogenic depositions.

H H Sedlacek.   

Abstract

Elimination of IC by the phagocytic system occurs mainly by macrophages and contrarotates to the pathogenic effect. Decisive to prevent systemic IC disease is the capacity of the phagocytic system. In the case of its saturation, the danger of the occurrence of IC disease is greatly enhanced. Conclusive evidence seems to exist that IC of extremely small or extremely high lattice structure (precipitates) are less pathogenic than soluble IC of medium network. Small IC in extreme antigen and antibody excess or precipitates exhibit a reduced complement activating potency. Small IC in extreme antigen or antibody excess hardly interact in vitro with membrane receptors and do not induce IC disease when injected or formed in vivo. Highly lattices IC, especially precipitates, are eliminated extremely quickly from the circulation, mainly by macrophages and there deposition in the kidney is significantly reduced. Thus, lack of quality of the antibody to precipitate the antigen and a reduced capacity and effectivity of the phagocytic system to eliminate the IC may be extremely important in the generation of IC diseases. Facing the overwhelming and partly even inconsistant data of this topic, one may doubt whether IC diseases may be regarded to be a defined and coherent disease. Too many variables and questions exist concerning the nature of the antigen, especially in tumor and autoimmune diseases, concerning the quality of the antibody and the characteristics of the pathogenic IC and concerning localization and the elimination process. Nevertheless, common pathophysiological pathways of IC diseases may be recognized.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6447230     DOI: 10.1007/bf01477835

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  261 in total

1.  [Effect of immune serum, IgG and various IgG fragments on in vitro phagocytosis and in vivo elimination of bacteria].

Authors:  W Ax; E J Kanzy; B Goronzi; F R Seiler
Journal:  Verh Dtsch Ges Inn Med       Date:  1978

2.  The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  H Permin; A Wiik
Journal:  Acta Pathol Microbiol Scand C       Date:  1978-10

3.  Heterogeneity of human lymphocyte Fc receptors. I. Differential susceptibility to proteolysis.

Authors:  B J Gormus; M Woodson; M E Kaplan
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

4.  The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression.

Authors:  E L Morgan; C H Tempelis
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

5.  Lung injury produced by immune complexes of varying composition.

Authors:  H Scherzer; P A Ward
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

6.  Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils.

Authors:  G Camussi; J M Mencia-Huerta; J Benveniste
Journal:  Immunology       Date:  1977-10       Impact factor: 7.397

7.  Induction of macrophage plasminogen activator by endotoxin stimulation and phagocytosis: evidence for a two-stage process.

Authors:  S Gordon; J C Unkeless; Z A Cohn
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

8.  A receptor for the third component of complement in the human renal glomerulus.

Authors:  M C Gelfand; M M Frank; I Green
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

9.  Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.

Authors:  M Takahashi; B F Tack; V Nussenzweig
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

10.  Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes.

Authors:  C L Anderson; H M Grey
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

View more
  2 in total

1.  The biological properties of immunoglobulin G and its split products [F(ab')2 and Fab].

Authors:  H H Sedlacek; P Gronski; T Hofstaetter; E J Kanzy; H U Schorlemmer; F R Seiler
Journal:  Klin Wochenschr       Date:  1983-08-01

2.  [Demonstration of circulating CEA or CEA-like antigens and immunoglobulin G containing immune complexes in colorectal carcinoma].

Authors:  R Pompecki
Journal:  Klin Wochenschr       Date:  1984-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.